These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 25269886)

  • 1. Design of silica carrier for controlled release of molsidomine: effect of preparation methods of silica matrixes and their composites with molsidomine on the drug release kinetics in vitro.
    Parfenyuk EV; Dolinina ES
    Eur J Pharm Biopharm; 2014 Nov; 88(3):1038-45. PubMed ID: 25269886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of Novel Delivery System for Cardiovascular Drug Molsidomine: Influence of Synthesis Method and Conditions on Molsidomine Release From Its Composites With Hydrophilic Silica In Vitro.
    Dolinina ES; Parfenyuk EV
    J Pharm Sci; 2016 Jun; 105(6):1952-1959. PubMed ID: 27238492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of Novel Warfarin-Silica Composite for Controlled Drug Release.
    Parfenyuk EV; Dolinina ES
    Pharm Res; 2017 Apr; 34(4):825-835. PubMed ID: 28138879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sol-gel Derived Warfarin - Silica Composites for Controlled Drug Release.
    Dolinina ES; Parfenyuk EV
    Curr Drug Deliv; 2017; 14(5):734-740. PubMed ID: 27774882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative study of adsorption capacity of mesoporous silica materials for molsidomine: effects of functionalizing and solution pH.
    Alyoshina NA; Agafonov AV; Parfenyuk EV
    Mater Sci Eng C Mater Biol Appl; 2014 Jul; 40():164-71. PubMed ID: 24857479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioactive silica-based drug delivery systems containing doxorubicin hydrochloride: in vitro studies.
    Prokopowicz M; Zegliński J; Gandhi A; Sawicki W; Tofail SA
    Colloids Surf B Biointerfaces; 2012 May; 93():249-59. PubMed ID: 22325320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hybrid organic-inorganic silica gel carriers with controlled drug-delivery properties.
    Contessotto L; Ghedini E; Pinna F; Signoretto M; Cerrato G; Crocellà V
    Chemistry; 2009 Nov; 15(44):12043-9. PubMed ID: 19774561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Magnetic silica hybrids modified with guanidine containing co-polymers for drug delivery applications.
    Timin AS; Khashirova SY; Rumyantsev EV; Goncharenko AA
    Mater Sci Eng C Mater Biol Appl; 2016 Jul; 64():20-28. PubMed ID: 27127024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of magnetic FexOy@silica-pillared clay (SPC) composites via a novel sol-gel route for controlled drug release and targeting.
    Mao H; Liu X; Yang J; Li B; Yao C; Kong Y
    Mater Sci Eng C Mater Biol Appl; 2014 Jul; 40():102-8. PubMed ID: 24857471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of synthesis conditions and release medium pH on release properties of acyclovir - mercaptopropyl modified silica composite.
    Dolinina ES; Akimsheva EY; Parfenyuk EV
    Drug Dev Ind Pharm; 2021 Oct; 47(10):1624-1632. PubMed ID: 35107404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposil, a promising composite material for drug storage and release.
    Bégu S; Aubert Pouëssel A; Lerner DA; Tourné-Péteilh C; Devoisselle JM
    J Control Release; 2007 Mar; 118(1):1-6. PubMed ID: 17250924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-vitro controlled release of doxorubicin from silica xerogels.
    Prokopowicz M
    J Pharm Pharmacol; 2007 Oct; 59(10):1365-73. PubMed ID: 17910811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro release of dexmedetomidine from silica xerogel monoliths: effect of sol-gel synthesis parameters.
    Kortesuo P; Ahola M; Kangas M; Yli-Urpo A; Kiesvaara J; Marvola M
    Int J Pharm; 2001 Jun; 221(1-2):107-14. PubMed ID: 11397572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel strategy to design sustained-release poorly water-soluble drug mesoporous silica microparticles based on supercritical fluid technique.
    Li-Hong W; Xin C; Hui X; Li-Li Z; Jing H; Mei-Juan Z; Jie L; Yi L; Jin-Wen L; Wei Z; Gang C
    Int J Pharm; 2013 Sep; 454(1):135-42. PubMed ID: 23871738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of Novel Oral Formulations of Disulfide Antioxidants Based on Porous Silica for Controlled Release of the Drugs.
    Dolinina ES; Parfenyuk EV
    Materials (Basel); 2021 Feb; 14(4):. PubMed ID: 33670671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PLGA/mesoporous silica hybrid structure for controlled drug release.
    Xue JM; Shi M
    J Control Release; 2004 Aug; 98(2):209-17. PubMed ID: 15262413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wet sol-gel derived silica for controlled release of proteins.
    Teoli D; Parisi L; Realdon N; Guglielmi M; Rosato A; Morpurgo M
    J Control Release; 2006 Dec; 116(3):295-303. PubMed ID: 17097181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioactive silica-based nanomaterials for doxorubicin delivery: evaluation of structural properties associated with release rate.
    Prokopowicz M
    Mater Sci Eng C Mater Biol Appl; 2013 Oct; 33(7):3942-50. PubMed ID: 23910300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of synthesis parameters of the sol-gel-processed spray-dried silica gel microparticles on the release rate of dexmedetomidine.
    Kortesuo P; Ahola M; Kangas M; Jokinen M; Leino T; Vuorilehto L; Laakso S; Kiesvaara J; Yli-Urpo A; Marvola M
    Biomaterials; 2002 Jul; 23(13):2795-801. PubMed ID: 12059031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymer-xerogel composites for controlled release wound dressings.
    Costache MC; Qu H; Ducheyne P; Devore DI
    Biomaterials; 2010 Aug; 31(24):6336-43. PubMed ID: 20510447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.